The Global NASH market valued at USD 3369.12 Million in the year 2020 is projected to grow due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. The market is expected to be driven by rise in advanced technology such as advanced clinical trials, special MRI technology, called MR-EFF (elastography fat fraction) to determine the percentage of fat and scarring present. This non-invasive diagnostic tool may eliminate the need for a liver biopsy.
Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.
North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.
On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.
Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.
Scope of the Report
Key Target Audience
Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.
North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.
On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.
Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.
Scope of the Report
- The report analyses the NASH Market by value (USD Million).
- The report analyses the NASH Market by Sales Channel - Hospital Pharmacy, Online Provider, Retail Pharmacy.
- The report analyses the NASH Market by By Drug Type - Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Others.
- The Global NASH Market has been analysed By Country - United States, Canada, Germany, France, United Kingdom, Italy, Japan, China, India, Mexico, Brazil
- The key insights of the report have been presented through the frameworks of SWOT analysis. Also, the attractiveness of the market has been presented by region, by Sales Channel, by Drug Type. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis AG, 3M Company, Zydus Cadila, Intercept Pharmaceuticals, SHIRE PLC , Allergan plc( Tobira), Genfit SA, Astra Zeneca, Horizon Therapeutics, Gilead Sciences.
- The report presents the analysis of NASH market for the historical period of 2016-2020 and the forecast period of 2021-2026.
Key Target Audience
- Healthcare an Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Table of Contents
1. Report Scope and Methodology1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. NASH Market: Product Overview
4. Global NASH Market: An Analysis
4.1 Market Size, By Value, Year 2016-2020
4.2 Market Size, By Value, Year 2021-2026
4.3 Impact of COVID-19 on NASH Market
5. Global NASH Market Segmentation, By Sales Channel (Value)
5.1 Global NASH Market: Segment Analysis
5.2 Competitive Scenario of NASH Market: By Sales Channel (2020 & 2026)
5.3 By Hospital Pharmacy - Market Size and Forecast (2016-2026)
5.4 By Online Provider- Market Size and Forecast (2016-2026)
5.5 By Retail Pharmacy-Market Size and Forecast (2016-2026)
6. Global NASH Market Segmentation, By Drug Type (Value)
6.1 Global NASH Market: Segment Analysis
6.2 Competitive Scenario of Global NASH Market: By Drug Type (2021 & 2026)
6.3 By Vitamin E & Pioglitazone - Market Size and Forecast (2016-2026)
6.4 By Ocaliva - Market Size and Forecast (2016-2026)
6.5 By Elafibranor - Market Size and Forecast (2016-2026)
6.6 By Selonsertib & Cenicriviroc - Market Size and Forecast (2016-2026)
6.7 By Others - Market Size and Forecast (2016-2026)
7. Global NASH Market: Regional Analysis
7.1 Competitive Scenario of Global NASHMarket: By Region (2021 & 2026)
8. North America NASH Market: An Analysis
8.1 North America NASH Market by value: Size and Forecast (2016-2026)
8.2 Major players in North America NASH Market
8.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
8.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
8.5 North America NASH Market: Country Analysis
8.6 Market Opportunity Chart of North America NASH Market- By Country, By Value (Year-2026)
8.7 Competitive Scenario of North America NASH Market - By Country (2020 & 2026)
8.8 United States NASH Market: Size and Forecast (2016-2026)
8.9 United States NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
8.10 Canada NASH Market: Size and Forecast (2016-2026)
8.11 Canada NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9. Europe NASH Market: An Analysis
9.1 Europe NASH Market by value: Size and Forecast (2016-2026)
9.2 Major players in European NASH Market
9.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
9.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
9.5 Europe NASH Market: Country Analysis
9.6 Market Opportunity Chart of Europe NASH Market - By Country, By Value (Year-2026)
9.7 Competitive Scenario of Europe NASH Market - By Country (2020 & 2026)
9.8 Germany NASH Market: Size and Forecast (2016-2026)
9.9 Germany NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9.10 France NASH Market: Size and Forecast (2016-2026)
9.11 France NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9.12 United Kingdom NASH Market: Size and Forecast (2016-2026)
9.13 United Kingdom NASH Market Segmentation By Sales Channel, By Drug Type(2016-2026)
9.14 Italy NASH Market: Size and Forecast (2016-2026)
9.15 Italy NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10. Asia Pacific NASH Market: An Analysis
10.1 Asia pacific NASH Market by value: Size and Forecast (2016-2026)
10.2 Major players in Asia Pacific NASH Market
10.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
10.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
10.5 Asia Pacific NASH Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific NASH Market - By Country, By Value (Year-2026)
10.7 Competitive Scenario of Asia Pacific NASH Market - By Country (2020 & 2026)
10.8 Japan NASH Market: Size and Forecast (2016-2026)
10.9 Japan NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10.10 China NASH Market: Size and Forecast (2016-2026)
10.11 China NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10.12 India NASH Market: Size and Forecast (2016-2026)
10.13 India NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
11. Latin America & Middle East Africa NASH Market: An Analysis
11.1 LAMEA NASH Market by value: Size and Forecast (2016-2026)
11.2 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
11.3 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
11.4 LAMEA NASH Market: Country Analysis
11.5 Market Opportunity Chart of LAMEA NASH Market - By Country, By Value (Year-2026)
11.6 Competitive Scenario of LAMEA NASH Market - By Country (2020 & 2026)
11.7 Mexico NASH Market: Size and Forecast (2016-2026)
11.8 Mexico NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
11.9 Brazil NASH Market: Size and Forecast (2016-2026)
11.10 Brazil NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
12. Global NASH Market Dynamics
12.1 Global NASH Market Drivers
12.2 Global NASH Market Restraints
12.3 Global NASH Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.1.1 Market Attractiveness Chart of Global NASH Market - By Sales Channel (Year 2026)
13.1.2 Market Attractiveness Chart of Global NASH Market - By Drug Type (Year 2026)
13.1.3 Market Attractiveness Chart of Global NASH Market - By Region (Year 2026)
14. Competitive Landscape
14.1 Market Share of global leading companies
14.2 SWOT Analysis
15.Company Profiles (Business Description, Financial Analysis, Business Strategy)
15.1 Novartis AG
15.2 3 M Company
15.3 Zydus Cadila
15.4 Intercept Pharmaceutical
15.5 Shire PLC
15.6 Allergan plc ( Tobira)
15.7 Genfit SA
15.8 Astra Zeneca
15.9 Horizon Therapeutics
15.10 Gilead ScienceList of Figures
Figure 1: Global NASH Market Size, By Value, 2016-2020 (USD Million)
Figure 2: Global NASH Market Size, By Value, 2021-2026 (USD Million)
Figure 3: Global Expenses (% GDP), 2015-2019
Figure 4: Current Health expenditure (% of GDP), 2015-2018
Figure 5: GDP per Capita Growth(annual %), 2015-2019
Figure 6: World Population 65 Years & Above (% of Total), 2015-2019
Figure 7: Global NASH Market- By Sales Channel Market Share, 2020 & 2026
Figure 8: Global NASH Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026
Figure 9: Global NASH Market- By Online Provider, By Value (USD Million), 2016-2026
Figure 10: Global NASH Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
Figure 11: Global NASH Market- By Drug Type Market Share, 2020 & 2026
Figure 12: Global NASH Market- By Vitamin E & Pioglitazone, By Value (USD Million), 2016-2026
Figure 13: Global NASH Market- By Ocaliva, By Value (USD Million), 2016-2026
Figure 14: Global NASH Market- By Elafibranor, By Value (USD Million), 2016-2026
Figure 15: Global NASH Market- By Selonsertib & Cenicriviroc , By Value (USD Million), 2016-2026
Figure 16: Global NASH Market- By Others , By Value (USD Million), 2016-2026
Figure 17: Global NASH Market- By Region Market Share, 2020 & 2026
Figure 18: North America NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 19: North America Current health expenditure(% of GDP)2014-2018
Figure 20: North America Population 65 & above2015-2019 (In %)
Figure 21: North America General government health expenditure 2014-2018 (In %)
Figure 22: North America Urban population, 2015-2019 (In %)
Figure 23: North America NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 24: North America NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 25: Market Opportunity Chart of North America NASH Market - By Country, By Value, 2026
Figure 26: North America Segment Analysis By Country, 2020, 2026
Figure 27: United States NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 28: United States Current health expenditure(% of GDP)
Figure 29: United States Population 65 & above(In %)
Figure 30: United States General Government Health Expenditure(% of GDP)
Figure 31: United States Urban population, 2016-2020 (In %)
Figure 32: United States NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 33: United States NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 34: Canada NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 35: Canada Current health expenditure(% of GDP)
Figure 36: Canada Population 65 & above(In %)
Figure 37: Canada General Government Health Expenditure(% of GDP)
Figure 38: Canada Urban population, 2016-2020 (In %)
Figure 39: Canada NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 40: Canada NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 41: Europe NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 42: Europe Current health expenditure(% of GDP)
Figure 43: Europe Population 65 & above(In %)2015-2019
Figure 44: Europe General Government Health Expenditure(% of GDP)
Figure 45: Europe Urban population, 2015-2019 (In %)
Figure 46: Europe NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 47: Europe NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 48: Market Opportunity Chart of Europe NASH Market - By Country, By Value, 2026
Figure 49: Europe NASH Market, By Country, 2020, 2026
Figure 50: Germany NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 51: Germany Current health expenditure(% of GDP)2014-2018
Figure 52: Germany Population 65 & above(In %)2015-2019
Figure 53: Germany General Government Health Expenditure(% of GDP)
Figure 54: Germany Urban population, 2015-2019 (In %)
Figure 55: Germany Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 56: Germany NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 57: France NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 58: France Current health expenditure(% of GDP)2014-2018
Figure 59: France Population 65 & above(In %)2015-2019
Figure 60: France General Government Health Expenditure(% of GDP)
Figure 61: France Urban population, 2015-2019 (In %)
Figure 62: France NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 63: France NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 64: United Kingdom NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 65: United Kingdom Current health expenditure(% of GDP)2014-2018
Figure 66: United Kingdom Population 65 & above(In %)2015-2019
Figure 67: United Kingdom General Government Health Expenditure(% of GDP)
Figure 68: United Kingdom Urban population, 2015-2019 (In %)
Figure 69: United Kingdom NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 70: United Kingdom NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 71: Italy NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 72: Italy Current health expenditure(% of GDP)2014-2018
Figure 73: Italy Population 65 & above(In %)2015-2019
Figure 74: Italy General Government Health Expenditure(% of GDP)
Figure 75: Italy Urban population, 2015-2019 (In %)
Figure 76: Italy NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 77: Italy NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 78: Asia Pacific NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 79: Asia Pacific Current health expenditure(% of GDP)
Figure 80: Asia Pacific Population 65 & above(In %)2015-2019
Figure 81: Asia Pacific General Government Health Expenditure(% of GDP)
Figure 82: Asia Pacific Urban population, 2015-2019 (In %)
Figure 83: Asia Pacific NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 84: Asia Pacific NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 85: Market Opportunity Chart of Asia Pacific NASH Market - By Country, By Value, 2026
Figure 86: Asia Pacific Segment Analysis By Country, 2020, 2026
Figure 87: Japan NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 88: Japan Current Health expenditure (% of GDP)
Figure 89: Japan Population ages 65 & above, 2016-2020 (In Million)
Figure 90: Japan General Government Health Expenditure(% of GDP)
Figure 91: Japan Urban Population (%) of total population, 2016-2020
Figure 92: Japan NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 93: Japan NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 94: China NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 95: China Current health expenditure 2014-2018 (In %)
Figure 96: China Population ages 65 & above, 2016-2020 (In Million)
Figure 97: China government Health spending, 2017-2050(USD per person)
Figure 98: China Urban Population (%) of total population, 2016-2020
Figure 99: China NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 100: China NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 101: India NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 102: India Current Health expenditure (% of GDP)
Figure 103: India Population ages 65 & above, 2016-2020 (In Million)
Figure 104: India General Government Health Expenditure(% of GDP)
Figure 105: India Urban Population (%) of total population, 2016-2020
Figure 106: India NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 107: India NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 108: LAMEA NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 109: LAMEA Current Health expenditure (% of GDP)
Figure 110: LAMEA Population ages 65 & above, 2016-2020 (In Million)
Figure 111: LAMEA General Government Health Expenditure(% of GDP)
Figure 112: LAMEA Urban Population (%) of total population, 2016-2020
Figure 113: LAMEA NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 114: LAMEA NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 115: Market Opportunity Chart of LAMEA NASH Market - By Country, By Value, 2026
Figure 116: LAMEA Segment Analysis By Country, 2020, 2026
Figure 117: Mexico NASH Market Size, By Value, 2016-2026 (USD Million)
Figure 118: Mexico Current health expenditure(% of GDP)
Figure 119: Mexico Population 65 & above(In Millions)
Figure 120: Mexico General Government Health Expenditure(% of GDP)
Figure 121: Mexico Urban population, 2016-2020 (In %)
Figure 122: Mexico NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 123: Mexico NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 124: Brazil NASH Market Size, By Value, 2016-2026 (USD Million
Figure 125: Brazil Current health expenditure(% of GDP)
Figure 126: Brazil Population 65 & above(In %)
Figure 127: Brazil Government Health Expenditure(% of GDP)
Figure 128: Brazil Urban population, 2016-2020 (In %)
Figure 129: Brazil NASH Market- By Sales Channel, By Value (USD Million), 2016-2026
Figure 130: Brazil NASH Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 131: Market Attractiveness Chart of Global NASH Market - By Sales Channel, 2026
Figure 132: Market Attractiveness Chart of Global NASH Market - By Drug Type, 2026
Figure 133: Market Attractiveness Chart of Global NASH Market - By Region, 2026
Figure 134: Market Share of Leading Global NASH Companies, 2020 (In %)
Figure 135: Novartis AG., Net Revenue, 2016-2020 (USD Million)
Figure 136: Novartis AG., Net Earnings, 2016-2020 (USD Million)
Figure 137: Novartis AG., By Product Segment (%), FY2020
Figure 138: Novartis AG. Net Sales, By Geographical Segment (%), FY2020
Figure 139: The 3M Company Net Sales, 2015-2029 (USD Million)
Figure 140: The 3M Company, Operating Profit , 2015-2019 (USD Million)
Figure 141: The 3M Company Net Sales, By Business Segment (%), FY2019
Figure 142: The 3M Company Net sales, By Geographical Segment (%), FY2019
Figure 143: Zydus Cadila Revenue, 2016-2020 (USD Million)
Figure 144: Zydus Cadila Retained Earnings, 2016-2020 (USD Million)
Figure 145: Zydus Cadila Revenue, By Business Segment (%), FY2020
Figure 146: Zydus Cadila Revenue, By Geographical Segment (%), FY2020
Figure 147: Intercept Pharmaceuticals Inc, 2016-2020 (USD Million)
Figure 148: Intercept Pharmaceuticals Inc, 2016-2020 (USD Million)
Figure 149: Intercept Pharmaceuticals Inc., By Geographical Segment (%), FY2020
Figure 150: Genfit SA, Revenue, 2016-2020 (USD Million)
Figure 151: Genfit SA, Retained Earnings, 2016-2020 (USD Million)
Figure 152: Astra Zeneca Revenue, 2016-2020 (USD Million)
Figure 153: Astra Zeneca, Operating Profit 2016-2020 (USD Million)
Figure 154: Astra Zeneca Revenue, By Business Segment (%), FY2020
Figure 155: Astra Zeneca Revenue, By Geographical Segment (%), FY2020
Figure 156: Horizon Therapeutics, Revenue, 2016-2020 (USD Million)
Figure 157: Horizon Therapeutics, Operating Profit 2016-2020 (USD Million)
Figure 158: Horizon Therapeutics Revenue, By Business Segment (%), FY2020
Figure 159: Horizon Therapeutics Revenue, By Geographical Segment (%), FY2020
Figure 160: Gilead Sciences, Revenue, 2016-2020 (USD Million)
Figure 161: Gilead Sciences, Net Income 2016-2020 (USD Million)
Figure 162: Gilead Sciences, Revenue, By Business Segment (%), FY2020
Figure 163: Gilead Sciences Revenue, By Geographical Segment (%), FY2020
Companies Mentioned
- Novartis AG
- 3M Company
- Zydus Cadila
- Intercept Pharmaceuticals
- SHIRE PLC
- Allergan plc( Tobira)
- Genfit SA
- Astra Zeneca
- Horizon Therapeutics
- Gilead Sciences.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | March 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 6.83 Billion |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
